Jiaqing Yi
University of Texas Southwestern Medical Center
H-index: 13
North America-United States
Top articles of Jiaqing Yi
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Clinical translation of biomarkers for ZL-1211, an anti-CLDN18. 2 antibody, in patients with advanced solid tumors from a phase I dose-escalation study | Cancer Research | Zhen Luo Xiao Wang Xuehuo Zeng Jiaqing Yi Tegan Burns | 2023/4/4 |
809 Anti-CLDN18. 2 antibody ZL-1211 enhances anti-tumor activities in combination with chemotherapy in gastric cancer models | Anthony Cao Qiuping Ye Karl Hsu Hua Gong Haiying Zhou | 2022/11/1 | |
PRC2 heterogeneity drives tumor growth in medulloblastoma | Cancer research | Jiaqing Yi BongWoo Kim Xuanming Shi Xiaoming Zhan Q Richard Lu | 2022/8/16 |
The CD47-targeting antibody ZL-1201 enhances anti-tumor activity of standard of care therapeutic antibodies by promoting phagocytosis in hematologic and solid tumor models | Cancer Research | Anthony Cao Jiaqing Yi Renyi Wu Christopher Szeto Quiping Ye | 2022/6/15 |
CD47-blocking antibody ZL-1201 promotes tumor-associated macrophage phagocytic activity and enhances the efficacy of the therapeutic antibodies and chemotherapy | Cancer Research Communications | Anthony Cao Jiaqing Yi Xinyan Tang Christopher W Szeto Renyi Wu | 2022/11/10 |
Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma | Cancer letters | Jiaqing Yi Xuanming Shi Zhenyu Xuan Jiang Wu | 2021/2/28 |
A Novel Oncogenic Function of PRC2 Heterogeneity in Medulloblastoma | bioRxiv | Jiaqing Yi Xuanming Shi Xiaoming Zhan Richard Q Lu Zhenyu Xuan | 2021/12/2 |
Neuronal activity-induced BRG1 phosphorylation regulates enhancer activation | Cell reports | Bongwoo Kim Yi Luo Xiaoming Zhan Zilai Zhang Xuanming Shi | 2021/7/13 |
